Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211129 | 0.94 | HPGD (0.47) | HPGDMEN1KMT2ALMNARORC | |
| SCHEMBL6211134 | 0.82 | HPGD (0.39) | HPGDMEN1KMT2ALMNARORC | |
| SCHEMBL11240083 | 0.80 | HPGD (0.47) | HPGDMEN1KMT2ALMNANPC1 | |
| SCHEMBL15688853 | 0.79 | HPGD (0.46) | HPGDMEN1KMT2ALMNARORC | |
| SCHEMBL19047046 | 0.78 | ALDH1A1 (0.50) | HPGDMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL13545160 | 0.77 | HPGD (0.54) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL31112245 | 0.77 | HPGD (0.54) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7299716 | 0.75 | AKT1 (0.49) | HPGDMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL25170278 | 0.75 | CYP1A2 (0.53) | MEN1KMT2ALMNAL3MBTL1NPC1 | |
| SCHEMBL9131611 | 0.75 | MEN1 (0.47) | HPGDMEN1KMT2ALMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137145-A1 | Metabolites of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and their use in the treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137145-A1 | Metabolites of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and their use in the treatment of urinary incontinence | PNMT, HNMT, PDE3A | HPGD 30/4885MEN1 3187/4885KMT2A 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.